10818-1-AP
antibody from Proteintech Group
Targeting: ERCC2
EM9, MAG, MGC102762, MGC126218, MGC126219, XPD
Antibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Western blot [1]
- Immunoprecipitation [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10818-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10818-1-AP, RRID:AB_2231330
- Product name
- ERCC2 antibody
- Antibody type
- Polyclonal
- Description
- ERCC2 antibody (Cat. #10818-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC, IP, WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Map-1a regulates Sertoli cell BTB dynamics through the cytoskeletal organization of microtubule and F-actin.
Triptolide enhances carboplatin-induced apoptosis by inhibiting nucleotide excision repair (NER) activity in melanoma.
NAT10 regulates the repair of UVB-induced DNA damage and tumorigenicity.
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.
Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer.
Aberrant methylation of nucleotide excision repair genes is associated with chronic arsenic poisoning.
MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: applications in clinical and basic research.
Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Wang L, Yan M, Bu T, Wu X, Li L, Silvestrini B, Sun F, Cheng CY, Chen H
Reproductive biology and endocrinology : RB&E 2024 Apr 3;22(1):36
Reproductive biology and endocrinology : RB&E 2024 Apr 3;22(1):36
Triptolide enhances carboplatin-induced apoptosis by inhibiting nucleotide excision repair (NER) activity in melanoma.
Wang G, Guo H, Ren Y, Chen W, Wang Y, Li J, Liu H, Xing J, Zhang Y, Li N
Frontiers in pharmacology 2023;14:1157433
Frontiers in pharmacology 2023;14:1157433
NAT10 regulates the repair of UVB-induced DNA damage and tumorigenicity.
Yang Z, Wilkinson E, Cui YH, Li H, He YY
Toxicology and applied pharmacology 2023 Oct 15;477:116688
Toxicology and applied pharmacology 2023 Oct 15;477:116688
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.
Jeon H, Byun J, Kang H, Kim K, Lee E, Kim JH, Hong CK, Song SW, Kim YH, Chong S, Kim JH, Nam SJ, Park JE, Lee S
Journal of translational medicine 2023 Feb 2;21(1):69
Journal of translational medicine 2023 Feb 2;21(1):69
Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer.
Tezuka S, Ueno M, Kobayashi S, Morimoto M, Ohkawa S, Hirotani A, Tozuka Y, Moriya S, Nakamura Y, Miyagi Y, Sugimori M, Maeda S
American journal of cancer research 2018;8(10):2096-2105
American journal of cancer research 2018;8(10):2096-2105
Aberrant methylation of nucleotide excision repair genes is associated with chronic arsenic poisoning.
Zhang A, Li H, Xiao Y, Chen L, Zhu X, Li J, Ma L, Pan X, Chen W, He Z
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2017 Jul;22(5):429-438
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2017 Jul;22(5):429-438
MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
Zhao H, Yu X, Ding Y, Zhao J, Wang G, Wu X, Jiang J, Peng C, Guo GZ, Cui S
Oncotarget 2016 Aug 16;7(33):53254-53268
Oncotarget 2016 Aug 16;7(33):53254-53268
Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: applications in clinical and basic research.
Zhao JY, Liu CQ, Zhao HN, Ding YF, Bi T, Wang B, Lin XC, Guo G, Cui SY
Methods (San Diego, Calif.) 2012 Oct;58(2):156-63
Methods (San Diego, Calif.) 2012 Oct;58(2):156-63
Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS
Cancer science 2009 Jul;100(7):1261-6
Cancer science 2009 Jul;100(7):1261-6
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HeLa cells were subjected to SDS PAGE followed by western blot with 10818-1-AP(ERCC2 antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- IP Result of anti-ERCC2 (IP:10818-1-AP, 5ug; Detection:10818-1-AP 1:500) with K-562 cells lysate 8000ug.
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The ERCC2 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human ERCC2. This antibody recognizes human antigen. The ERCC2 antibody has been validated for the following applications: ELISA, WB, IHC, IP analysis.